These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26447877)

  • 1. Venous thrombosis in patients with high-grade glioma.
    Taillibert S; Taillandier L; Le Rhun E
    Curr Opin Oncol; 2015 Nov; 27(6):516-21. PubMed ID: 26447877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents.
    Perry JR
    Curr Opin Neurol; 2010 Dec; 23(6):592-6. PubMed ID: 20881488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous Thromboembolism in Patients with High-Grade Glioma.
    Cote DJ; Dawood HY; Smith TR
    Semin Thromb Hemost; 2016 Nov; 42(8):877-883. PubMed ID: 27574964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracranial hemorrhage in cancer patients treated with anticoagulation.
    Weinstock MJ; Uhlmann EJ; Zwicker JI
    Thromb Res; 2016 Apr; 140 Suppl 1():S60-5. PubMed ID: 27067980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?
    Jo J; Donahue J; Sarai G; Petroni G; Schiff D
    Neuro Oncol; 2022 Mar; 24(3):455-464. PubMed ID: 34383073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombosis in brain tumors.
    Jo JT; Schiff D; Perry JR
    Semin Thromb Hemost; 2014 Apr; 40(3):325-31. PubMed ID: 24599439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation in the Setting of Primary and Metastatic Brain Tumors.
    Mantia C; Zwicker JI
    Cancer Treat Res; 2019; 179():179-189. PubMed ID: 31317488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours.
    Chai-Adisaksopha C; Linkins LA; ALKindi SY; Cheah M; Crowther MA; Iorio A
    Thromb Haemost; 2017 Feb; 117(3):589-594. PubMed ID: 28078351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.
    Diaz M; Jo J
    Curr Oncol Rep; 2022 Apr; 24(4):493-500. PubMed ID: 35179708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study.
    Vitale FV; Rotondo S; Sessa E; Parisi A; Giaimo V; D'Angelo A; Antonelli G; Romeo P; Ferraù F
    J Oncol Pharm Pract; 2012 Mar; 18(1):10-6. PubMed ID: 21228085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.
    Mantia C; Uhlmann EJ; Puligandla M; Weber GM; Neuberg D; Zwicker JI
    Blood; 2017 Jun; 129(25):3379-3385. PubMed ID: 28468796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism in malignant gliomas.
    Jenkins EO; Schiff D; Mackman N; Key NS
    J Thromb Haemost; 2010 Feb; 8(2):221-7. PubMed ID: 19912518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation.
    Zwicker JI; Karp Leaf R; Carrier M
    J Thromb Haemost; 2016 Sep; 14(9):1736-40. PubMed ID: 27306689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboembolic disease in patients with high-grade glioma.
    Perry JR
    Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv73-80. PubMed ID: 23095833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer.
    Farge D; Bounameaux H; Brenner B; Cajfinger F; Debourdeau P; Khorana AA; Pabinger I; Solymoss S; Douketis J; Kakkar A
    Lancet Oncol; 2016 Oct; 17(10):e452-e466. PubMed ID: 27733271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
    Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
    Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis.
    Porfidia A; Giordano M; Sturiale CL; D'Arrigo S; Donadini MP; Olivi A; Ageno W; Pola R
    Brain Behav; 2020 Jun; 10(6):e01638. PubMed ID: 32314875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unanswered questions in venous thromboembolism.
    Weitz JI
    Thromb Res; 2009; 123 Suppl 4():S2-S10. PubMed ID: 19303498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based approach.
    Pangilinan JM
    J Pharm Pract; 2010 Aug; 23(4):294-302. PubMed ID: 21507829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.